# Shenzhen Sinobio Biopharmaceutical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/shenzhen-sinobio-biopharmaceutical

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Latest round: Angel (May 24, 2025)
- Investors on record: 3

## About

Founded in 2024 and based in Shenzhen, China, Shenzhen Sinobio Biopharmaceutical operates as a biotechnology service provider focusing on the research and development of recombinant botulinum toxin. In May 2025, the company closed an angel funding. Shenzhen Sinobio Biopharmaceutical has an exclusive green preparation process for synthetic biology-botulinum toxin, an AI botulinum protein design and directed evolution platform, a botulinum protein function high-throughput screening platform, and a number of independent recombinant botulinum toxin core technologies.

## Funding rounds

- Angel, May 24, 2025 — Green Pine Capital Partners, Leaguer Group, Shenzhen Qianhai Star River Capital Management Co., Ltd.

## Investors

- Green Pine Capital Partners (https://capitalatlas.ai/funds/green-pine-capital-partners) — Angel
- Leaguer Group (https://capitalatlas.ai/funds/leaguer-group) — Angel
- Shenzhen Qianhai Star River Capital Management Co., Ltd. — Angel